Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

Genetically engineered mosquitoes halt Dengue spread

Genetically engineered mosquitoes halt Dengue spread

New antibody-drug conjugate shows promising activity in salivary gland tumors

New antibody-drug conjugate shows promising activity in salivary gland tumors

Bile acids help norovirus to infect cells of the small intestine

Bile acids help norovirus to infect cells of the small intestine

New dementia vaccine may proceed to clinical trials after successful testing

New dementia vaccine may proceed to clinical trials after successful testing

New antibody shows promise in active lupus

New antibody shows promise in active lupus

Study: Blocking IL1α protein decreases severity of inflammation in Crohn's disease

Study: Blocking IL1α protein decreases severity of inflammation in Crohn's disease

Immunotherapy: A promising new alternative to cancer therapies

Immunotherapy: A promising new alternative to cancer therapies

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

Experimental therapies offer patients a greater chance of surviving Ebola virus disease

Experimental therapies offer patients a greater chance of surviving Ebola virus disease

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

Lonza launches new basal and feed medium to optimize protein production

Lonza launches new basal and feed medium to optimize protein production

Understanding Monoclonal Antibody Unfolding and Aggregation

Understanding Monoclonal Antibody Unfolding and Aggregation

Atlantic Health System Cancer Care enrolling patients in five pancreatic cancer studies

Atlantic Health System Cancer Care enrolling patients in five pancreatic cancer studies

BioStreamline project outcomes

BioStreamline project outcomes

BioStreamline: Streamlining the development of next generation biotherapeutics

BioStreamline: Streamlining the development of next generation biotherapeutics

Dupilumab provides clinical benefit to adolescents with moderate-to-severe atopic dermatitis

Dupilumab provides clinical benefit to adolescents with moderate-to-severe atopic dermatitis

Analyses of two clinical trials predict response to asthma drug by COPD patients

Analyses of two clinical trials predict response to asthma drug by COPD patients

Lung cancer may soon be picked up by a blood test

Lung cancer may soon be picked up by a blood test

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.